Patent ID: 11957739
Assignee: DANA-FARBER CANCER INSTITUTE, INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  G | IPC A  G

Claim 2:
3. The method of claim 1, wherein
a) the agent comprises a RHOA dominant negative polypeptide sequence of SEQ ID NO: 1;
b) the agent is a RHOA dominant negative polypeptide, and further comprises a heterologous polypeptide fused thereto, optionally wherein (i) the fused polypeptide has greater half-life and/or cell permeability than the corresponding unfused RHOA dominant negative polypeptide, or biologically active fragment thereof; and/or (ii) the heterologous polypeptide is an Fc domain and/or a cell permeable peptide; and/or
c) the agent is a nucleic acid that is comprised within an expression vector or a cell.